Andersson, Claes R.
Selvin, Tove
Blom, Kristin
Rubin, Jenny
Berglund, Malin
Jarvius, Malin
Lenhammar, Lena
Parrow, Vendela
Loskog, Angelica
Fryknäs, Mårten
Nygren, Peter
Larsson, Rolf
Funding for this research was provided by:
Lions cancerforskningsfond, Mellansverige Uppsala-Örebro
Cancerfonden (CAN 2016/335)
Vetenskapsrådet (2016-01112)
Article History
Received: 3 December 2019
Accepted: 19 June 2020
First Online: 4 August 2020
Competing interests
: R.L., P.N. and M.F. are co-founders and shareholders of Repos Pharma AB, a small Swedish research and development company dedicated to investigations of drug repositioning in the cancer area. AL is chairman of the board. The present work was funded only by academic grants. The remaining authors declare no competing interests.